Galapagos NV will discontinue its Phase II trial for GLPG0259 in rheumatoid arthritis (RA) following a planned interim analysis that did not support continuing development of the drug for RA. No serious adverse events or safety signals were reported, but the Interim Review Committee recommended that study be discontinued due to limited efficacy potential. Galapagos plans to complete a full analysis of the data before making a decision on the next steps for GLPG0259, including other indications. ...